Company news - Shenzhen Efung Investment Management Co. Ltd.

Company news

A Century of Passive Immunity Rewritten — Today, by China.

July 21, 2026 — Zhuhai Trinomab Pharmaceutical Co., Ltd. (Stock Code: 688806.SH) officially debuted on the STAR Market (SSE Sci-Tech Innovation Board) at an IPO price of RMB 14.46 per share.This is far more than a Biotech's bell-ringing ceremony. It marks the first time in over a century that an original Chinese-developed antibody therapeutic has entered the capital markets to combat tetanus. It signals the closing chapter of an era — the old world of passive immunity, reliant on horse serum, burdened by allergy risks, and constrained by plasma supply, is turning a page. Notably, Trinomab also represents the second IPO for Efung Capital in 2026, following Northsea Medical (688712.SH).01 – China Overtakes on the Tetanus Prevention TrackTetanus — an ancient and merciless name.On battlefields without medical intervention, in rural delivery rooms using unsterile methods, on construction sites punctured by rusty nails — its fatality rate once approached 100%.Clinical data shows tha...

2026 - 07 - 21
Efung News | China's Original "Intervention Without Implantation": Weiguang Medical's 355 nm Cold La

Recently, LightSaber, a single-use laser optical fiber catheter independently developed by Zhongke Rongguang, a subsidiary of Weiguang Medical, officially received approval for market launch from the National Medical Products Administration (NMPA) of China (Registration Certificate No.: 20263011418).The catheter is intended for use in combination with the previously approved FastErazer 355 nm cold laser atherectomy device (Registration Certificate No.: 20263011296) for the pretreatment of lower extremity atherosclerotic stenosis (including in-stent restenosis) and occlusive lesions, to facilitate recanalization.When used together with the FastErazer 355 nm cold laser atherectomy device, the catheter enables efficient and precise ablation of atherosclerotic plaque, thereby enlarging the luminal diameter and promoting the absorption of antiproliferative drugs to restore vascular patency. The system delivers ultraviolet cold laser at an output wavelength of 355 nm and a pulse width of 15 ...

2026 - 07 - 17
Efung Knowledge Planet | US$60 Billion in Outbound Deals in Q1: Top 10 Life Sciences Keywords for 20

China's life sciences industry has transformed into an innovation center of global significance, built upon accelerated regulatory pathways, strong policy support, and rapidly improving R&D efficiency across pharmaceuticals, medical devices, and biotechnology.Approximately 2,390 words | 5–6 min readFor a long time, China's innovative drug story was about the journey from "me-too" to "me-better." But halfway through 2026, the narrative has shifted—valuation is no longer driven by vision, but by hard metrics: pipeline data, deal values, and enrollment speed.KPMG's recently released 2026 China Life Sciences Sector Overview and Outlook (1) validates this transformation with data: China's life sciences industry is emerging as a globally significant innovation hub, with accelerating regulatory pathways, robust policy support, and visibly improved R&D efficiency across pharma, devices, and biotech. Digital technologies—AI, robotics, and sm...

2026 - 07 - 16
A Monkey Costs Over 200,000 RMB – Are This Year's Monkeys Already Booked Out?

On July 15, the A-share market showed notable structural divergence, with the innovative drug sector leading gains across the board. Multiple sub-segments including CRO, weight-loss drugs, recombinant proteins, cellular immunotherapy, and generic innovation drugs all surged over 4%. On the same day, a piece of news about laboratory monkeys began circulating in the industry: the price of cynomolgus monkeys has exceeded 200,000 RMB per animal, and many monkey farms have told buyers that "this year's monkeys are already fully booked."These two seemingly unrelated pieces of information point to the same logic – R&D activity in innovative drugs is rebounding, and laboratory monkeys are the most direct "thermometer" of this recovery.01 Why Are Monkey Prices Rising Again?Recently, Red Star Capital Bureau visited experimental monkey breeding enterprises in Guangxi, Guangdong, Sichuan and other regions, and found that most monkey farms have already had this year'...

2026 - 07 - 15
Efung News | Jingze Bio's JZB32 Project Included in National Science and Technology Major Project –

Recently, Jingze Bio's core pipeline project JZB32 (Recombinant Human Truncated Plasminogen Injection) was officially included in the National Science and Technology Major Project for Innovative Drug R&D, under the initiative "Innovative Drug R&D for Major Fundus Diseases Based on Cell Growth Factors."On July 5, 2026, the project kick-off meeting was grandly held at Wenzhou Medical University, bringing together top experts in ophthalmology and pharmaceutical sciences from across China to conduct in-depth discussions on collaborative R&D of original biologics for fundus diseases.This marks a national-level honor for Jingze Bio in the field of innovative drug R&D, and signifies that the company's technological strength and strategic positioning in fundus disease innovative drug development have received high recognition at the national level.JZB32 is a recombinant human truncated plasminogen (Ocriplasmin) injection independently developed by Jingze Bio, ...

2026 - 07 - 13
Efung News | 2025 State Science and Technology Awards Announced! Investee Enterprises of Efung Capit

On July 8, 2026, the 2025 State Science and Technology Awards Conference was grandly held at the Great Hall of the People in Beijing. Xi Jinping, General Secretary of the Communist Party of China Central Committee, President of the People’s Republic of China, and Chairman of the Central Military Commission, attended the conference, presented awards to laureates of the State Preeminent Science and Technology Award and other winners, and delivered an important speech.General Secretary Xi emphasized that the period covered by the 15th Five-Year Plan marks a critical stage for advancing the building of a country strong in science and technology. We must seize historic opportunities, rise to the challenges of our times, accelerate the achievement of high-level self-reliance and strength in science and technology, forge ahead firmly toward the goal of building a country strong in science and technology by 2035, and underpin and guide Chinese modernization with solid scientific and technologi...

2026 - 07 - 10

Copyright © 2018 2021.All Rights Reserved 粤公网安备44030402002338号 Rhino Cloud provides enterprise cloud services 犀牛云提供云计算服务